Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AnaptysBio Inc

ANAB
Current price
16.24 USD +0.8 USD (+5.18%)
Last closed 15.59 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 398 628 000 USD
Yield for 12 month -41.29 %
Week
Month
Year
ANAB
21.11.2021 - 28.11.2021

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801

Analytics

WallStreet Target Price

27 USD

P/E ratio

Dividend Yield

Current Year

+10 287 000 USD

Last Year

+63 175 000 USD

Current Quarter

+3 318 000 USD

Last Quarter

+3 460 000 USD

Current Year

+10 287 000 USD

Last Year

+63 175 000 USD

Current Quarter

+3 318 000 USD

Last Quarter

+3 460 000 USD

Key Figures ANAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -150 778 000 USD
Operating Margin TTM -1137.19 %
PE Ratio
Return On Assets TTM -17.12 %
PEG Ratio
Return On Equity TTM -74.28 %
Wall Street Target Price 27 USD
Revenue TTM 14 960 000 USD
Book Value 4.53 USD
Revenue Per Share TTM 0.55 USD
Dividend Share
Quarterly Revenue Growth YOY 156.6 %
Dividend Yield
Gross Profit TTM -78 511 000 USD
Earnings Share -5.42 USD
Diluted Eps TTM -5.42 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ANAB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ANAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ANAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.255
Price Sales TTM 26.6463
Enterprise Value EBITDA -0.0298
Price Book MRQ 3.3113

Financials ANAB

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ANAB

For 52 weeks

13.36 USD 32.44 USD
50 Day MA 16.73 USD
Shares Short Prior Month 5 050 415
200 Day MA 19.56 USD
Short Ratio 21.66
Shares Short 4 942 284
Short Percent 27.35 %